Logo image of PTRA

PROTERRA INC (PTRA) Stock Fundamental Analysis

NASDAQ:PTRA - Nasdaq - US74374T1097 - Common Stock - Currency: USD

0.067  -0.02 (-25.56%)

After market: 0.065 0 (-2.99%)

Fundamental Rating

2

Overall PTRA gets a fundamental rating of 2 out of 10. We evaluated PTRA against 128 industry peers in the Machinery industry. PTRA has a bad profitability rating. Also its financial health evaluation is rather negative. PTRA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year PTRA has reported negative net income.
PTRA had a negative operating cash flow in the past year.
PTRA Yearly Net Income VS EBIT VS OCF VS FCFPTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -100M -200M -300M

1.2 Ratios

PTRA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTRA Yearly ROA, ROE, ROICPTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -10 -20 -30 -40

1.3 Margins

PTRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTRA Yearly Profit, Operating, Gross MarginsPTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 -20 -40 -60 -80 -100

2

2. Health

2.1 Basic Checks

PTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTRA has been increased compared to 1 year ago.
The debt/assets ratio for PTRA is higher compared to a year ago.
PTRA Yearly Shares OutstandingPTRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 50M 100M 150M 200M
PTRA Yearly Total Debt VS Total AssetsPTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -2.67, we must say that PTRA is in the distress zone and has some risk of bankruptcy.
PTRA has a Altman-Z score of -2.67. This is amonst the worse of the industry: PTRA underperforms 90.63% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that PTRA is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.00, PTRA belongs to the best of the industry, outperforming 85.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.67
ROIC/WACCN/A
WACC6.89%
PTRA Yearly LT Debt VS Equity VS FCFPTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.39 indicates that PTRA should not have too much problems paying its short term obligations.
PTRA has a worse Current ratio (1.39) than 82.03% of its industry peers.
A Quick Ratio of 0.76 indicates that PTRA may have some problems paying its short term obligations.
The Quick ratio of PTRA (0.76) is worse than 81.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 0.76
PTRA Yearly Current Assets VS Current LiabilitesPTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 200M 400M 600M 800M

4

3. Growth

3.1 Past

PTRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -194.37%.
Looking at the last year, PTRA shows a very strong growth in Revenue. The Revenue has grown by 29.59%.
EPS 1Y (TTM)-194.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.04%
Revenue 1Y (TTM)29.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.95%

3.2 Future

The Earnings Per Share is expected to grow by 20.03% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 46.82% on average over the next years. This is a very strong growth
EPS Next Y-20.84%
EPS Next 2Y29.75%
EPS Next 3Y25.51%
EPS Next 5Y20.03%
Revenue Next Year47.51%
Revenue Next 2Y52.46%
Revenue Next 3Y59.79%
Revenue Next 5Y46.82%

3.3 Evolution

PTRA Yearly Revenue VS EstimatesPTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
PTRA Yearly EPS VS EstimatesPTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1 -1.5

1

4. Valuation

4.1 Price/Earnings Ratio

PTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTRA Price Earnings VS Forward Price EarningsPTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTRA Per share dataPTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as PTRA's earnings are expected to grow with 25.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.75%
EPS Next 3Y25.51%

0

5. Dividend

5.1 Amount

No dividends for PTRA!.
Industry RankSector Rank
Dividend Yield N/A

PROTERRA INC

NASDAQ:PTRA (8/16/2023, 8:17:12 PM)

After market: 0.065 0 (-2.99%)

0.067

-0.02 (-25.56%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)08-09 2023-08-09/amc
Earnings (Next)N/A N/A
Inst Owners0.16%
Inst Owner Change0%
Ins Owners60.57%
Ins Owner Change0%
Market Cap15.26M
Analysts78.33
Price Target3.73 (5467.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-295.67%
Min EPS beat(2)-295.67%
Max EPS beat(2)-295.67%
EPS beat(4)0
Avg EPS beat(4)-166.66%
Min EPS beat(4)-295.67%
Max EPS beat(4)-98.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-10.08%
Min Revenue beat(2)-10.19%
Max Revenue beat(2)-9.97%
Revenue beat(4)1
Avg Revenue beat(4)-3.32%
Min Revenue beat(4)-10.19%
Max Revenue beat(4)16.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-88.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.06
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS1.5
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 265.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 0.76
Altman-Z -2.67
F-Score3
WACC6.89%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.04%
EPS Next Y-20.84%
EPS Next 2Y29.75%
EPS Next 3Y25.51%
EPS Next 5Y20.03%
Revenue 1Y (TTM)29.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.95%
Revenue Next Year47.51%
Revenue Next 2Y52.46%
Revenue Next 3Y59.79%
Revenue Next 5Y46.82%
EBIT growth 1Y-59.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.14%
EBIT Next 3Y35.23%
EBIT Next 5Y26.57%
FCF growth 1Y-137.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-134.92%
OCF growth 3YN/A
OCF growth 5YN/A